Short-term efficacy and side effects of bevacizumab or rh-endostatin combined with chemotherapy in treatment of locally advanced EGFR wild-type non-small cell lung cancer
10.3872/j.issn.1007-385x.2019.04.009
- VernacularTitle:贝伐单抗或血管内皮抑制素联合化疗治疗局部晚期EGFR野生型非小 细胞肺癌的近期疗效及毒副反应
- Author:
LU Mingqing
1
;
ZHOU Hongmei
1
;
ZHOU Xuguang
2
Author Information
1. Department of Respiratory and Critical Care Medicine, Zhongshan Hospital Affiliated to Guangdong Medical University, Zhongshan Chen Xinghai Hospital
2. Department of Emergency, Zhongshan Hospital Affiliated to Guangdong Medical University, Zhongshan Chen Xinghai Hospital,
- Publication Type:Journal Article
- Keywords:
advanced non-small cell lung cancer;
bevacizumab;
rh-endostatin;
docetaxel;
cisplatin;
short-term efficacy;
toxicity and side effects
- From:
Chinese Journal of Cancer Biotherapy
2019;26(4):426-430
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To investigate the short-term efficacy and toxicity of bevacizumab combined with DP or rh-endostatin（recombinant human vascular endostatin injection）combined with DP in locally advanced EGFR wild-type non-small cell lung cancer (NSCLC). Methods: Seventy-two patients with treatment of locally advanced EGFR wild-type NSCLC admitted to the Department of Respiratory Medicine of Zhongshan Hospital Affiliated to Guangdong Medical University from January 2014 to January 2017 were divided into bevacizumab group (34 cases) and rh-endostatin group (38 cases) according to the random number method. The former group was treated with bevacizumab combined with docetaxel and cisplatin, while the latter was treated with rh-endostatin combined with docetaxel and cisplatin. According to RECISIT 1.1 standard, the changes of lesion size before and after treatment in two groups were evaluated. Serum levels of vascular endothelial growth factor (VEGF), carcinoembryonic antigen (CEA), cytokeratin 21-1 fragment (CYFRA21-1), squamous cell carcinoma antigen (SCC) were measured. The adverse reactions during treatment were also evaluated. Results: In bevacizumab group, patients with CR, PR, SD, PD, DCR and ORR were 2 cases, 12 cases, 15 cases, 5 cases, 41.18% and 85.29%, respectively. In rh-endostatin group, patients with CR, PR, SD, PD, DCR, ORR were 2 cases, 16 cases, 14 cases, 6 cases, 47.37% and 84.21%, respectively. The DCR in rh-endostatin group was significantly higher than that in bevacizumab group (P<0.05).The serum levels of VEGF and CEAin rh-endostatin group decreased more obvious than those in bevacizumab group (all P<0.05). The incidence of gastrointestinal reaction, skin reaction and cardiac toxicity in rh-endostatin group was higher than that in bevacizumab group, while the incidence of bleeding in bevacizumab group was higher than that in rh-endostatin group (all P<0.05). Conclusion: In patients with locally advanced EGFR wild-type NSCLC, rh-endostatin combined with DP regimen is better than bevacizumab combined with DPregimen. In clinical practice, corresponding treatment regimen can be selected according to different characteristics of patients, so as to minimize the toxic reaction during treatment and avoid clinical risk.
- Full text:20190409.pdf
